Division of Endocrine and Minimally Invasive Surgery, Department of Surgery, New York Presbyterian Hospital-Weill Cornell Medical College, New York, USA.
Ann Surg Oncol. 2012 Mar;19(3):973-80. doi: 10.1245/s10434-011-2029-0. Epub 2011 Aug 31.
Intercellular adhesion molecule-1 (ICAM-1) is implicated in carcinogenesis. In this study we examined the expression of ICAM-1 in papillary thyroid cancer (PTC). We hypothesized that ICAM-1 correlates with indicators of tumor aggressiveness in PTC.
Thirty-five primary and metastatic PTCs, five follicular adenomas, five Hashimoto thyroiditis, five nodular hyperplasia, and eight normal thyroid tissue samples were analyzed for ICAM-1 gene expression using quantitative reverse-transcription polymerase chain reaction (RT-PCR). ICAM-1 gene expression was analyzed at protein level by immunohistochemistry (IHC) using a semiquantitative score. Gene expression and intensity levels were correlated with markers of tumor aggressiveness including BRAF V600E mutation, tumor size, extrathyroidal extension (ETE), angiolymphatic invasion, and lymph node metastasis.
ICAM-1 gene expression was higher in PTC (p = 0.01) and lymph node metastases (p = 0.03) when compared with benign tumors and Hashimoto's. Furthermore, PTCs exhibiting BRAF V600E mutation (p = 0.01), ETE (p < 0.01), and lymph node metastasis (p = 0.02) were associated with higher ICAM-1 levels. Gene expression correlated with protein levels on IHC. Additionally, poorly differentiated thyroid carcinoma had a higher ICAM-1 intensity score compared with well-differentiated carcinoma (p = 0.03).
ICAM-1 expression is upregulated in papillary thyroid carcinoma. Furthermore, ICAM-1 upregulation correlated with aggressive tumor features such as BRAF V600E mutation, ETE, and lymph node metastasis, suggesting that ICAM-1 plays a role in thyroid cancer progression.
细胞间黏附分子-1（ICAM-1）与癌症的发生有关。在这项研究中，我们研究了 ICAM-1 在甲状腺乳头状癌（PTC）中的表达。我们假设 ICAM-1 与 PTC 中肿瘤侵袭性的指标相关。
使用定量逆转录聚合酶链反应（RT-PCR）分析 35 例原发性和转移性 PTC、5 例滤泡性腺瘤、5 例桥本甲状腺炎、5 例结节性增生和 8 例正常甲状腺组织样本的 ICAM-1 基因表达。使用半定量评分的免疫组织化学（IHC）分析 ICAM-1 基因表达的蛋白水平。基因表达和强度水平与肿瘤侵袭性的标志物相关，包括 BRAF V600E 突变、肿瘤大小、甲状腺外延伸（ETE）、血管淋巴管侵犯和淋巴结转移。
与良性肿瘤和桥本甲状腺炎相比，PTC（p=0.01）和淋巴结转移（p=0.03）中的 ICAM-1 基因表达更高。此外，具有 BRAF V600E 突变（p=0.01）、ETE（p<0.01）和淋巴结转移（p=0.02）的 PTC 与更高的 ICAM-1 水平相关。基因表达与 IHC 上的蛋白水平相关。此外，与高分化癌相比，低分化甲状腺癌的 ICAM-1 强度评分更高（p=0.03）。
ICAM-1 在甲状腺乳头状癌中表达上调。此外，ICAM-1 的上调与侵袭性肿瘤特征相关，如 BRAF V600E 突变、ETE 和淋巴结转移，提示 ICAM-1 在甲状腺癌的进展中发挥作用。
